Loading stock data…
$1.60-0.02 (-1.53%)
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.
enGene Therapeutics Inc. in the Healthcare sector is trading at $1.60 with a market capitalization of $108M. Wall Street consensus targets $3.29 (7 analysts), implying a +104.7% move over the next 12 months. The stock is currently near its 52-week low of $1.40, remaining 66.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$34.01M↓ | -$31.97M↓ | -$31.18M↑ | -$39.48M↓ | -$29.95M |
| Net Income | -$32.50M↓ | -$30.23M↓ | -$29.75M↑ | -$37.88M↓ | -$28.99M |
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimo...